ReviewFrontiers in cell and developmental biology2026
Spatial proteomics: technical evolution and applications in cancer research.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spatial proteomics is reshaping tissue-based cancer research by linking protein expression to cellular identity, tissue architecture and clinical behavior. Conventional proteomics has provided powerful tools for protein identification and quantification, but most bulk workflows erase the spatial relationships that define tumor ecology. In contrast, spatial proteomics combines multiplexed imaging, mass spectrometry-based tissue analysis, region-selected profiling and computational spatial statistics to measure proteins in their native tissue context. This review summarizes the development of proteomics from early separation and mass spectrometry technologies to current spatial platforms. It then focuses on cancer applications, including tumor heterogeneity, tumor microenvironment, antitumor immunity, immunotherapy response, spatial biomarkers and treatment resistance. Across these areas, spatial proteomics is most valuable when it converts descriptive tissue patterns into testable hypotheses about cell states, neighborhood interactions and therapeutic vulnerabilities. The field now needs standardized workflows, clinically anchored cohorts and functional validation to move from high-dimensional tissue maps to robust translational tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.